WallStSmart

Heartflow, Inc. Common Stock (HTFL)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 32095% more annual revenue ($56.67B vs $176.03M). NVS leads profitability with a 24.7% profit margin vs -66.3%. NVS earns a higher WallStSmart Score of 51/100 (C-).

HTFL

Avoid

30

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 5.0

NVS

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 9.0Value: 3.3Quality: 5.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for HTFL.

NVSSignificantly Overvalued (-52.2%)

Margin of Safety

-52.2%

Fair Value

$109.78

Current Price

$142.94

$33.16 premium

UndervaluedFair: $109.78Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HTFL1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
40.5%10/10

Revenue surging 40.5% year-over-year

NVS5 strengths · Avg: 9.0/10
Market CapQuality
$280.79B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
30.8%10/10

Every $100 of equity generates 31 in profit

Profit MarginProfitability
24.7%9/10

Keeps 25 of every $100 in revenue as profit

Operating MarginProfitability
27.8%8/10

Strong operational efficiency at 27.8%

Free Cash FlowQuality
$1.64B8/10

Generating 1.6B in free cash flow

Areas to Watch

HTFL4 concerns · Avg: 3.0/10
Price/BookValuation
8.4x4/10

Trading at 8.4x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-111.4%2/10

ROE of -111.4% — below average capital efficiency

Free Cash FlowQuality
$-12.49M2/10

Negative free cash flow — burning cash

NVS4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
2.2%4/10

2.2% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

PEG RatioValuation
2.532/10

Expensive relative to growth rate

EPS GrowthGrowth
-11.6%2/10

Earnings declined 11.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : HTFL

The strongest argument for HTFL centers on Revenue Growth. Revenue growth of 40.5% demonstrates continued momentum.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at 27.8%.

Bear Case : HTFL

The primary concerns for HTFL are Price/Book, EPS Growth, Return on Equity.

Bear Case : NVS

The primary concerns for NVS are Revenue Growth, Altman Z-Score, PEG Ratio.

Key Dynamics to Monitor

HTFL profiles as a hypergrowth stock while NVS is a value play — different risk/reward profiles.

HTFL is growing revenue faster at 40.5% — sustainability is the question.

NVS generates stronger free cash flow (1.6B), providing more financial flexibility.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NVS scores higher overall (51/100 vs 30/100), backed by strong 24.7% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Heartflow, Inc. Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases globally. The company is headquartered in Mountain View, California.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?